Trial: 202107012

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab
after Resection of Recurrent/Second Primary Head and Neck Squamous
Cell Carcinoma with High Risk Features

Phase

II

Principal Investigator

Jackson, Ryan

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov